[go: up one dir, main page]

MX2022000794A - Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina. - Google Patents

Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina.

Info

Publication number
MX2022000794A
MX2022000794A MX2022000794A MX2022000794A MX2022000794A MX 2022000794 A MX2022000794 A MX 2022000794A MX 2022000794 A MX2022000794 A MX 2022000794A MX 2022000794 A MX2022000794 A MX 2022000794A MX 2022000794 A MX2022000794 A MX 2022000794A
Authority
MX
Mexico
Prior art keywords
imidazo
pyridin
pyrimidine derivatives
formula
inhibitors
Prior art date
Application number
MX2022000794A
Other languages
English (en)
Inventor
Dieter Dorsch
Andreas Blum
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2022000794A publication Critical patent/MX2022000794A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de la fórmula I (ver Fórmula) en la cual R1, R2, V, X, Y y Z tienen los significados indicados en la reivindicación 1, que son inhibidores de cinasa c-Kit, y pueden emplearse para el tratamiento del cáncer.
MX2022000794A 2019-07-24 2020-07-22 Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina. MX2022000794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188031 2019-07-24
PCT/EP2020/070616 WO2021013864A1 (en) 2019-07-24 2020-07-22 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2022000794A true MX2022000794A (es) 2022-02-16

Family

ID=67438678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000794A MX2022000794A (es) 2019-07-24 2020-07-22 Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina.

Country Status (13)

Country Link
US (1) US20220267320A1 (es)
EP (1) EP4003992A1 (es)
JP (3) JP7601852B2 (es)
KR (2) KR102894509B1 (es)
CN (2) CN118955500A (es)
AR (1) AR119461A1 (es)
AU (1) AU2020318710B2 (es)
BR (1) BR112022001158A2 (es)
CA (1) CA3148227A1 (es)
IL (1) IL289953B2 (es)
MX (1) MX2022000794A (es)
TW (1) TWI868186B (es)
WO (1) WO2021013864A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN120379972A (zh) * 2022-12-20 2025-07-25 深圳湾实验室 一种靶向usp1的小分子抑制剂及其应用
WO2025248485A1 (en) 2024-05-31 2025-12-04 Idrx, Inc. Pharmaceutical compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US7977336B2 (en) * 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
NZ590320A (en) * 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US20120190666A1 (en) * 2009-05-13 2012-07-26 Amgen Inc. Heteroaryl Compounds as PIKK Inhibitors
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US10370371B2 (en) * 2013-08-30 2019-08-06 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors

Also Published As

Publication number Publication date
TW202118762A (zh) 2021-05-16
JP7601852B2 (ja) 2024-12-17
KR102894509B1 (ko) 2025-12-02
AU2020318710B2 (en) 2025-11-20
IL289953B1 (en) 2024-11-01
IL289953A (en) 2022-03-01
IL289953B2 (en) 2025-03-01
BR112022001158A2 (pt) 2022-05-17
JP2025186243A (ja) 2025-12-23
AU2020318710A1 (en) 2022-03-10
TWI868186B (zh) 2025-01-01
JP2025060626A (ja) 2025-04-10
CN114174293A (zh) 2022-03-11
EP4003992A1 (en) 2022-06-01
WO2021013864A1 (en) 2021-01-28
JP2022542072A (ja) 2022-09-29
AR119461A1 (es) 2021-12-22
CN118955500A (zh) 2024-11-15
KR20220041133A (ko) 2022-03-31
US20220267320A1 (en) 2022-08-25
CA3148227A1 (en) 2021-01-28
CN114174293B (zh) 2024-08-06
JP7730407B2 (ja) 2025-08-27
KR20250174707A (ko) 2025-12-12

Similar Documents

Publication Publication Date Title
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX390348B (es) Compuestos de benzimidazol como inhibidores de c-kit
AR067505A1 (es) Derivados de pirimidinil-piridazinona
MX382436B (es) Derivados de quinolin-2-ona.
ECSP088598A (es) Derivados de piridazinona
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
PE20161388A1 (es) Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
BR112015022011A2 (pt) derivados de imidazo[4,5-c]piridina e pirrolo[2,3-c] piridina como inibidores de ssao
CR20180172A (es) Derivados de 8-[6-[3-(amino) propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
SI3357922T1 (sl) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2022000794A (es) Derivados de 4-(imidazo[1,2-a]piridin-3-il)pirimidina.
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.